logo-loader
viewEquiniti

Equiniti plans rights issue for takeover of Wells Fargo's share registration business

Equiniti said shareholders will vote on its proposed acquisition of the Wells Fargo share registration business later this month

Wells Fargo
Wells Fargo has said it wants to focus on growth areas of the business

Equiniti Group (LON:EQN) has announced further details of its plans to raise £122mln through a rights issue to support its proposed takeover of Wells Fargo's share registration business.

Equiniti, a share registration and investor services company, will offer 4,309,150 new shares at 190p each by way of a fully underwritten rights issue to qualifying shareholders. The issue price represents a discount of 31.7% to the share price at the close of markets on 11 September.

Proceeds of the rights issues will used to help fund the group’s planned US$227mln acquisition of Wells Fargo Share Registration & Services (WFSS). Equiniti will also use £120mln of debt facilities to finance the integration costs of the takeover.    

The deal is subject to approval by shareholders at a general meeting on 28 September.

Equiniti said its directors unanimously consider that the acquisition to be in the best interests of the company and recommended that shareholders vote in favour of the deal.

The group expects the new shares in the rights issue to be admitted to the London Stock Exchange on 29 September following approval by the stock exchange and the Financial Conduct Authority.

Shares edged up 0.12% to 296.40p in morning trading. 

Equiniti announced its plans in July, saying it expects the acquisition to boost its earnings in the first year of its ownership.

Wells Fargo's share registrar arm is the third largest in America, providing shareholder services to more than 1,200 firms in the country with clients including Hewlett-Packard, General Electric and Berkshire Hathaway. Wells Fargo has said it wants to focus on growth areas of the business.

 

Quick facts: Equiniti

Price: 219.099 GBX

LSE:EQN
Market: LSE
Market Cap: £798.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

2 hours, 22 minutes ago

RNS

Holding(s) in Company

1 week, 2 days ago

Director/PDMR Shareholding

1 week, 3 days ago

Total Voting Rights

2 weeks, 3 days ago

Holding(s) in Company

4 weeks, 2 days ago

Total Voting Rights

on 29/11/19

2 min read